MedPath

Lupin Receives FDA Approval for Generic Adderall XR Capsules

• Lupin has secured FDA approval for its generic version of Adderall XR extended-release capsules, addressing attention deficit hyperactivity disorder (ADHD). • The approved ANDA covers multiple dosages (5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg) of the mixed salts amphetamine product. • This generic equivalent aims to compete in a market with estimated annual sales of $865 million in the U.S. • Lupin will manufacture the drug at its Somerset facility in the US, expanding its portfolio of generic formulations.

Lupin Limited has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, a generic equivalent of Takeda Pharmaceuticals USA, Inc.’s Adderall XR. The approval spans dosages of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
The approved capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in both adult and pediatric patients aged six years and older. ADHD is a neurodevelopmental disorder affecting millions, characterized by inattention, hyperactivity, and impulsivity.

Market and Manufacturing

The market for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules (RLD Adderall XR) had estimated annual sales of USD 865 million in the US, according to IQVIA MAT September 2024 data. Lupin plans to manufacture the product at its Somerset facility in the US.
Lupin Limited, headquartered in Mumbai, India, distributes its pharmaceutical products across over 100 markets globally. The company specializes in a range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Granules Pharmaceuticals Secures FDA Approval for Lisdexamfetamine Dimesylate Chewable Tablets

Granules Pharmaceuticals has received FDA approval for its ANDA for Lisdexamfetamine Dimesylate Chewable Tablets, used to treat ADHD and BED.
The approved drug, bioequivalent to Takeda's Vyvanse, comes in strengths of 10 mg to 60 mg, addressing critical shortages in the U.S. market.

Lupin Gains FDA Approval for Generic Adderall XR for ADHD Treatment

Lupin has received FDA approval for its generic version of Adderall XR, an extended-release capsule used to treat ADHD in adults and children.
The approved Abbreviated New Drug Application (ANDA) includes multiple dosage strengths, ranging from 5 mg to 30 mg.

Lupin Gains USFDA Approval for Generic Adderall XR for ADHD Treatment

Lupin has received USFDA approval for its generic version of Adderall XR extended-release capsules, a mixed salts amphetamine product.
The approved drug, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules, treats ADHD in adults and children.

Elite Pharmaceuticals Gains FDA Approval for Generic Vyvanse

Elite Pharmaceuticals has received FDA approval for its generic version of Vyvanse (Lisdexamfetamine Dimesylate) capsules, offering seven strengths from 10 mg to 70 mg.
The newly approved generic drug is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) across a range of patient needs.

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

Elite Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse (Lisdexamfetamine Dimesylate).
The generic Vyvanse will be available in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules, indicated for ADHD treatment.

Alembic Pharmaceuticals Receives USFDA Approval for Generic Hypertension Treatment

Alembic Pharmaceuticals has secured USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, used to treat hypertension.
The approved drug will be available in strengths of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, offering varied dosage options.

Lupin Gains FDA Approvals for HIV, Cystic Fibrosis, and Heart Failure Generics

Lupin receives FDA approval for generic Sacubitril/Valsartan tablets, a heart failure therapy, targeting a $6.06 billion market.
Tentative FDA approval granted to Lupin for generic Abacavir/Dolutegravir/Lamivudine tablets, an HIV treatment for pediatric patients.

FDA Approves Once-Nightly Sodium Oxybate (Lumryz) for Pediatric Narcolepsy

The FDA has approved sodium oxybate (Lumryz) for treating cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients aged 7 and older.
Lumryz is the first and only FDA-approved once-at-bedtime oxybate for pediatric narcolepsy, offering a convenient alternative to twice-nightly regimens.

Onyda XR, First Liquid Non-Stimulant for ADHD, Now Available in the US

Tris Pharma's Onyda XR (clonidine hydrochloride), the first liquid, non-stimulant medication for ADHD, is now available in the U.S. for pediatric patients aged 6 and older.
Approved by the FDA in May 2024, Onyda XR can be used as a monotherapy or as an adjunctive therapy with CNS stimulants for ADHD treatment.

Strides Pharma Secures USFDA Approval for Generic Theophylline Extended-Release Tablets

Strides Pharma Global, a subsidiary of Strides Pharma Science, has received USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg, a generic version of Schering Corp's THEO-DUR.
These tablets are indicated for managing symptoms and reversible airflow obstruction linked to chronic asthma and other chronic lung diseases like emphysema and chronic bronchitis.

Reference News

[1]
Lupin receives US FDA approval for generic Adderall XR extended-release capsules
pharmabiz.com · Nov 20, 2024

Lupin Limited received FDA approval for its ANDA of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dex...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy